Phase 1 Prostate Cancer Trial, Recruiting NCT07537010 Sponsor: Chunjing Yu Condition: Prostate Cancer
Back to Prostate Cancer

Phase 1 Prostate Cancer Trial, Recruiting

NCT07537010
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able to understand the study and are willing to sign a written consent form, and can attend all required visits and follow the study requirements
  • Men aged 18 years or older
  • People who have been diagnosed with prostate adenocarcinoma (a specific type of prostate cancer), confirmed through a laboratory tissue or cell test
  • People whose testosterone levels are at castrate levels, meaning very low (below 50 ng/dL or 1.7 nmol/L), typically achieved through ongoing hormone therapy
  • People whose scan results using a 68Ga-PSMA PET/CT scan (a specialised imaging test for prostate cancer) came back positive
  • People with a general health and activity level rated at 0, 1, or 2 on a standard medical scale, meaning they are able to carry out at least some daily activities (confirm with trial site)
  • People who have prostate cancer that has spread to other parts of the body, is no longer responding to hormone treatment, and has continued to grow despite previous treatments
  • People who have at least one area of cancer spread (metastatic lesion) visible at the start of the study
  • People whose kidneys, liver, and other organs are functioning well enough to meet the study's requirements (confirm with trial site)
  • People whose side effects from any previous cancer treatments have mostly resolved or are mild

Who may not be able to join:

  • People who have received other systemic (whole-body) cancer treatments within the 4 weeks before joining the study
  • People whose life expectancy is estimated by their doctor to be less than 6 months
  • People whose bone scan shows a pattern called a "superscan," which indicates very widespread cancer spread throughout the bones (confirm with trial site)
  • People who have significant other medical conditions that are not well-controlled and could affect their safety or the study results
  • People who have had a serious allergic reaction or severe intolerance to the study drug or closely related medicines
  • People who have medical, mental health, or practical circumstances that, in the treating doctor's judgement, would make it unsafe or not possible for them to follow the study requirements

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 15312238622

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Chunjing Yu
Registry
ClinicalTrials.gov
Start date
27 August 2025
Est. completion
30 June 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence and severity of Treatment-Emergent Adverse Events (TEAEs); Occurrence of Dose-Limiting Toxicities (DLTs); Absorbed Dose; Effective Half-Life

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov